Mission Wealth Management LP purchased a new position in shares of Becton Dickinson and Co (NYSE:BDX) during the 4th quarter, Holdings Channel reports. The fund purchased 1,677 shares of the medical instruments supplier’s stock, valued at approximately $359,000.
A number of other large investors have also modified their holdings of the business. Suntrust Banks Inc. lifted its position in Becton Dickinson and by 2.7% during the 4th quarter. Suntrust Banks Inc. now owns 44,690 shares of the medical instruments supplier’s stock worth $9,566,000 after buying an additional 1,185 shares in the last quarter. Harfst & Associates Inc. bought a new stake in Becton Dickinson and during the 4th quarter worth about $239,000. Roberts Glore & Co. Inc. IL lifted its position in Becton Dickinson and by 8.6% during the 4th quarter. Roberts Glore & Co. Inc. IL now owns 5,909 shares of the medical instruments supplier’s stock worth $1,265,000 after buying an additional 467 shares in the last quarter. Baird Financial Group Inc. lifted its position in Becton Dickinson and by 52.7% during the 4th quarter. Baird Financial Group Inc. now owns 52,429 shares of the medical instruments supplier’s stock worth $11,223,000 after buying an additional 18,084 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board lifted its position in Becton Dickinson and by 29.5% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 42,067 shares of the medical instruments supplier’s stock worth $9,005,000 after buying an additional 9,589 shares in the last quarter. 77.50% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the transaction, the director now owns 295,753 shares in the company, valued at approximately $64,420,918.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 1.00% of the stock is currently owned by corporate insiders.
Several equities research analysts have commented on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research report on Tuesday, October 31st. Morgan Stanley boosted their price target on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Bank of America reissued a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research report on Friday, January 19th. Piper Jaffray Companies reissued an “overweight” rating and set a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Finally, Evercore ISI initiated coverage on shares of Becton Dickinson and in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $237.27.
Becton Dickinson and Co (NYSE BDX) opened at $219.82 on Wednesday. The firm has a market cap of $59,337.46, a PE ratio of 167.80, a PEG ratio of 1.59 and a beta of 1.12. Becton Dickinson and Co has a 52 week low of $175.66 and a 52 week high of $248.39. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping the consensus estimate of $2.41 by $0.07. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. Becton Dickinson and’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.33 EPS. research analysts predict that Becton Dickinson and Co will post 10.94 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be paid a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.36%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 229.01%.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://ledgergazette.com/2018/02/21/1677-shares-in-becton-dickinson-and-co-bdx-acquired-by-mission-wealth-management-lp.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.